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Abstract
Hepatitis B virus (HBV) associated end-stage liver diseases are the leading causes of liver transplantation (LT) in Taiwan.
Relapse of hepatitis B occurs after LT, raising the risk of graft failure and reducing patient survival. Although several oral
antiviral agents have been approved for anti-HBV treatment, lamivudine (LAM) remained to be the most widely used
preventive regimen in Taiwan. While several clinical predictors have been identified for hepatitis B relapse, the predictive
roles of the histopathological characteristics in liver explants as well as the genotypic features of the viruses in pre-LT serum
samples have not been assessed. Between September 2002 and August 2009, 150 consecutive hepatitis B surface antigen
(HBsAg) positive patients undergoing LT were included for outcome analysis following assessment of the
clinicopathological and virological factors prior to LT. Kaplan-Meier analyses discovered that pre-operative LAM treatment
#3 months; membranous distribution and higher expression of tissue HBsAg in liver explants; preoperative viral load §10
6
copies/ml; and presence of large fragment (.100 base pairs) pre-S deletion (LFpreSDel) correlated significantly with
hepatitis B relapse. Multivariate Cox regression analysis showed that the presence of LFpreSDel (P=0.001) and viral load
§10
6 copies/mL (P=0.023) were independent predictors for hepatitis B relapse. In conclusion, besides high viral load,
LFpreSDel mutation is an important independent predictor for hepatitis B relapse after LT. More aggressive preventive
strategies should be applied for patients carrying these risk factors.
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Introduction
Hepatitis B virus (HBV) infection remains a major public health
problem worldwide with approximately 2 billion people having
been infected and 350 million of these patients becoming chronic
carriers [1]. HBV infection is endemic in Taiwan and the carrier
rate of HBsAg in general population has been as high as 15–20%
before initiation of the vaccination program. Infection of HBV is
associated with a wide spectrum of clinical manifestations, ranging
from acute or fulminant hepatitis to various forms of chronic
diseases, including asymptomatic carriers, chronic hepatitis, liver
cirrhosis, and hepatocellular carcinoma (HCC) [1,2]. Since the
first successful human liver transplantation (LT) in 1963 by Starzl
et al [3], LT has become the treatment of choice in eligible
patients with hepatic failure or early HCC in many medical
centers. However, the results of early experience with LT for HBV
related diseases were unsatisfactory in the 1980s, as majority of
patients developed recurrent HBV infection in the early post-LT
period, leading to loss of the allograft with reduced patient survival
[4,5]. Patients with active viral replication prior to transplantation
are particularly at risk of hepatitis B relapse. On the other hand, in
patients harboring a lower viral load prior to LT, a favorable long-
term outcome is generally expected. This observation led to an
effective strategy to improve LT outcome through reduction of
pre-transplantation HBV viral load [6].
The clinical outcomes of patients as well as graft survivals in
HBV LT recipients have been dramatically improved with the
introduction of long-term hepatitis B immune globulin (HBIG)
therapy and the availability of highly effective antiviral agents such
as lamivudine (LAM) and adefovir dipivoxil [7]. Furthermore,
combination prophylaxis with the use of HBIG and antiviral
agents has reduced the risk of hepatitis B relapse to 10% or less in
the first 2 years following transplantation [8,9,10,11,12]. As a
result, the outcomes of patients with acute and chronic HBV
related liver diseases undergoing LT are now similar to or better
than those with non-HBV related liver transplantation [13,14].
While the prophylactic therapies in the management of HBV in
transplant recipients represent a significant step in LT, there
remain controversies and challenges that have not been adequate-
ly resolved. Long-term prophylaxis with HBIG is expensive and
has been associated with the development of surface antigen
mutations. Similarly, emergence of drug resistance caused by
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occurs with prolonged LAM therapy. The choice of antiviral drugs
or drug combinations and duration of prophylaxis are still being
debated in the literature. It has been suggested that short-term
rather than life-long HBIG could be used with or without
combination of oral nucleos(t)ide analogs in low risk patients
[15,16,17]. This strategy emphasized the need to identify risk
factors capable of predicting hepatitis B relapse after LT for
optimal prophylaxis. While several studies have identified clinical
predictors such as high viral loads [18,19], cumulative corticoste-
roid dose for immunosuppression [20], recurrence of HCC post
LT [21,22], HBIG monoprophylaxis (12) [12] and prolonged
LAM therapy [19,23], none has assessed the predictive roles of the
histopathological characteristics in liver explants as well as the
genotypic features of the viruses in pre-LT serum samples. The
aim of this study, therefore, was to evaluate the predictive value of
all the aforementioned clinicopathological and genotypic virolog-
ical factors in hepatitis B relapse after LT in patients receiving
combination treatment of short-term HBIG and life-long LAM.
Methods
Ethics statement
This study was conducted under the approval of the Institutional
Review Board, Chang Gung Memorial Hospital, Taiwan. Written
informed consent was obtained from all patients included.
Patients
Between September 2002 and August 2009, 150 consecutive
HBsAg positive patients undergoing LT in Chang Gung Memorial
Hospital Linko medical center were included under informed
consent. The indications for LT in this group of patients included
HCC, decompensated liver diseases and fulminant hepatic failure.
All patients were alive more than 3 months after LT and were
followed up monthly in the outpatient clinic. This study was
approved by the institutional review board at Chang Gung
Memorial Hospital.
HBV prophylaxis protocol
Prior to transplantation, LAM (Zeffix, GlaxoSmithKline,
Middlesex, UK) (100 mg/day orally) was commenced in 79
patients. Among them, 39 patients received the prophylactic
therapy for more than one month. Eight patients were confirmed
to develop YMDD mutation at transplantation, and subsequently
received adefovir (Hepsera, GlaxoSmithKline, Middlesex, UK)
monotherapy. During LT operation, intravenous HBIG (Hepa-
tect, Biotest Pharma, Dreieich, Germany) (10,000 IU) was
administered in the anhepatic phase, followed by 2,000 IU daily
after LT for one week. All patients received daily oral LAM
(n=142) or adefovir (n=8) antiviral therapy after LT.
Virological assays for HBV
Prior to transplantation, viral markers including HBsAg,
antibody against hepatitis B surface antigen (anti-HBs), hepatitis
B e antigen (HBeAg), antibody against hepatitis B e antigen (anti-
HBe), antibody against hepatitis B core antigen (anti-HBc) and
antibody against hepatitis C virus (anti-HCV) were routinely
measured using commercially available assays for the donors and
recipients. The sources of these standard tests were described
previously [24]. Serum viral DNA was extracted using commercial
kits (QIAamp DNA Blood and Tissue Mini Kit; QIAGEN Inc.,
Valencia, CA). The HBV-DNA concentration was quantified
using Roche TaqMan HBV Monitor (Roche Diagnostics, Basel,
Switzerland) with a detection limit of 69 copies/mL. The
preoperative serum samples were used for virological analyses
including viral genotypes, large and short fragments pre-S
deletions, precore G1896A mutation and basal core promoter
A1762T/G1764A mutations. The methods of these genotypic
assays were described previously [24]. Following LT, liver function
profiles were monitored daily for the first week, weekly for the first
month, and monthly thereafter. HBV serological markers were
monitored weekly for the first month and monthly thereafter.
Hepatitis B recurrence was defined as reappearance of HBsAg or
HBV-DNA in the serum. Experiments were conducted to identify
LAM or adefovir resistance-associated viral mutations in patients
with recurrent hepatitis B.
Immunosuppression
The immunosuppressive agents including calcineurin inhibitors
and corticosteroids were administered for all eligible patients after
LT. No intraoperative high dose methylprednisolone (Solu-
medrol, Pfizer, New York City, NY) was given in our medical
center. The corticosteroids were gradually tapered over 3 months
after LT. Oral tacrolimus (PROGRAFT, Astellas, Tokyo, Japan)
was commenced 48 hours after transplantation and the dose was
adjusted to maintain serum trough levels over 5–10 ng/ml.
Alternatively, mycophenolate mofetil (CellCept, Roche, Basel,
Switzerland) was administered in selected patients with renal
insufficiency. A liver biopsy was performed if acute cellular
rejection was suspected clinically or biochemically. In case of acute
graft rejection, an intravenous bolus dose (500 mg) of methyl-
prednisolone was administered for 1–3 days, followed by rapid
weaning of intravenous corticosteroid over 5–7 days. Oral
prednisolone was slowly tapered for 3–6 months after the pulsed
steroid therapy was administered.
Histopathology analysis of liver explants
Four specimens were randomly sampled from sections of
explanted liver for histopathological analyses using hematoxylin
and eosin staining. The Ishak histology score was used to assess the
severity of hepatitis [25]. Immunohistochemistry for HBsAg and
HBcAg were performed on formalin fixed paraffin embedded
tissues using mouse monoclonal antibodies (Clone 1044/341 and
LF161, respectively, Abnova Corporation, Taipei, Taiwan). The
tissue blocks from each explanted liver were sectioned at 3 mm and
placed onto positively charged slides. Slides were then stained
using the Bond-Max autostainer (Leica Microsystems Inc., Buffalo
Grove, IL) according to the manufacturer’s protocol. Antibody
detection was performed using the biotin free Bond Polymer
refined Detection System (Leica Microsystems). Slides were
counterstained with hematoxylin. The percentage of chromogen
containing cells were estimated in the ranges of 0%, ,5%, 5%–
25%, 26%–50%, .51% and semiquantitively scored as 0 to 4.
The characteristics of HBsAg stain were further classified into
cytoplasmic or membranous expression. The characteristics of
HBcAg stain were classified into nuclear or cytoplasmic expres-
sion. Histopathological assessment was performed by pathologists
who specialized in liver pathology and was blinded to the clinical
and virological data.
Statistical analysis
Fisher’s exact and Pearson’s x
2 tests were used, where
appropriate, to compared dichotomous variables. Student’s t test
was used to compare parametric data. Kaplan-Meier method was
used to compare the overall survivals or hepatitis B relapse free
survivals between subgroups. In the survival analysis, the cutoffs of
parametric data were obtained following a published procedure
[24]. Statistical differences in survival analysis were calculated
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analysis were included for multivariate analysis using stepwise Cox
proportional hazard model. All statistical analyses were performed
using SPSS version 13.0 (SPSS, Chicago, Illinois, USA).
Results
Clinical characteristics of the patients and transplantation
outcomes
The baseline clinical parameters and operation associated
variables were listed in Table S1. The immunosuppressant used
and occurrence of infections were listed in Table S2. Of the 150
patients included, 123 (84.0%) received LT because of advanced
liver cirrhosis with or without HCC, 20 (13.3%) because of acute
on chronic liver failure and 7 (4.7%) because of fulminant
hepatitis. HCC was found in the explanted livers in 78 (52.0%)
patients. The median follow-up period of the 150 patients was
37.5 months (range, 3.2–96.6). The patient’s outcomes were
shown in Figure 1A. All patients were tested negative for HBsAg
and HBV-DNA immediately after LT. In this study, reappear-
ance of HBsAg or serum HBV-DNA was considered hepatitis B
relapse. As such, 33 patients (22.2%) experienced reappearance
of HBsAg during the follow-ups. Of them, 18 (12.0%) patients
also experienced reappearance of serum HBV-DNA. Most of
these patients (15 of 18 patients) with re-appearance of viremia
after LT were found to develop LAM-resistant (YMDD) mutation
and add-on Adefovir were given as anti-viral therapy. None of
our patients was positive for serum HBV-DNA but negative for
HBsAg. The median time to hepatitis B relapse was 12.2 months
(range, 2.8–73.2). The cumulative hepatitis B relapse rates were
10.5% in the first year, 19.6% in the third year, and 29.7% in the
fifth year, respectively. Twenty-seven (18%) patients died. Of
them, 8 died of recurrent HCC, 4 died of acute liver failure due
to hepatitis B relapse and the other 13 patients died of non-HBV
related diseases including sepsis and biliary complications. The
median time to death after LT was 8.4 months (range, 3.2–72.6)
in these patients. Kaplan-Meier analysis showed that hepatitis B
relapse was significantly associated with shorter overall survival
(P=0.0003; Figure 1B).
Clinical factors associated with hepatitis B relapse after
LT
The baseline clinical parameters and operation associated
variables were compared between patients with (n=33) and
without (n=117) hepatitis B relapse (Table S3). Kaplan-Meier
analysis indicated that only preoperative LAM treatment #3
months was significantly associated with shorter hepatitis B relapse
free survival (P=0.040) (Figure 1C). In 29 patients receiving LAM
treatment .3 months prior to LT, 3 (10.3%) had a viral load
.10
6 copies/mL at the time of LT. In comparison, 36 of 121
(29.8%) patients receiving LAM treatment #3 months had a viral
load .10
6 copies/mL (P=0.035).
The information of steroid and immunosuppressant usages as
well as treatment of acute rejection with steroid bolus was given in
Table S2. There were ten patients suffered from acute rejections
within half year before the date of HBV relapse or last follow-up.
We did not use anti-IL2 receptor monoclonal antibody for
treatment of acute rejection. Episodes of infections by bacteria,
fungus, or cytomegalovirus were also listed in Table S2. None of
these factors were associated with HBV relapse.
There were 52 LT patients receiving a graft from Anti-HBc
positive donors (See Table S1). Seven of these 52 patients had
HBV relapse. The donors of these 7 patients were negative for
HBsAg and positive for anti-HBs antibody. It was difficult to prove
that the reactivation was donor derived. However, it was
interesting to note that one patient with HBV relapse had altered
HBV genotypes before operation and after relapse (C to B). This
patient might have a donor derived hepatitis B reactivation.
Virological and histopathological factors associated with
hepatitis B relapse after LT
The genotypic features of HBV were assessed using preoper-
ative serum samples. Because of low viral loads and undetectable
HBV-DNA levels in some patients, the results of genotype, large
fragment pre-S deletion (LFpreSDel), short fragment pre-S
deletion, basal core promoter A1762T/G1764A mutations, and
precore G1896A mutation were obtained in 140 (93.3%), 136
(90.0%), 135 (90.0%), 113 (75.3%), and 113 (75.3%) patients,
respectively. Kaplan-Meier analysis was performed for these
factors (Table S4). It was found that a preoperative viral load
§10
6 cps/ml (P=0.004) and the presence of LFpreSDel
(P=0.003) correlated significantly with hepatitis B relapse
(Figure 2A to C). Viral genotypes and basal core promoter
A1762T/G1764A mutations were not found to be associated with
hepatitis B relapse (Figure 2D). The presence of precore G1896A
mutation was borderline associated with a shorter hepatitis B
relapse-free survival (P=0.064; Figure 2E).
Immunohistochemistry analysis was performed to detect tissue
expression of HBsAg (Figure 3A) and HBcAg (Figure 3B). All
explanted livers were submitted for Ishak score assessment and
immunohistochemistry analysis except for one sample, in which
the explanted liver tissue was presented with massive tissue
necrosis, preventing accurate evaluation. The staining patterns
and intensities were categorized and the hepatitis B relapse free
survivals were compared (Table S4). The results showed that the
membranous staining pattern (P=0.035) and high expression
intensity (P=0.047) of HBsAg in the explanted livers were
associated with hepatitis B relapse (Figure 3C and D). However,
no association could be found between HBcAg expression and
hepatitis B relapse (Table S4).
To gain more insight into understanding the histopathological
changes in the explanted livers from patients with high
(§10
6 cps/ml) and low (,10
6 cps/ml) serum levels, the histo-
pathological characteristics were compared. Patients with high
viral load had a higher Ishak score (P=0.005; attributive to focal
necrosis and portal inflammation) as well as a higher percentage of
nuclear (P=0.004) and cytoplasmic (P,0.0001) HBcAg expres-
sion. In contrast, when compared between patients with and
without LFpreSDel, it was found that the presence of LFpreSDel
mutation was associated with a lower Ishak score (P=0.003;
attributive to periportal inflammation and necrosis). Of note was
that neither large nor short fragment pre-S deletion was associated
with the staining patterns or expression intensities of tissue HBsAg
in this study. The presence of precore G1896A mutation was
associated with higher expression intensities of HBsAg (P=0.035)
and confluent necrosis (P=0.030) in the explanted liver tissues.
The presence of basal core promoter mutations was borderline
associated with a higher percentage of cytoplasmic HBcAg
expression (P=0.048).
Identification of independent predictors for hepatitis B
relapse
Five factors significantly associated with hepatitis B relapse free
survival (by Kaplan-Meier analysis) were included for multivariate
analysis using Cox proportional hazard model. They were
duration of preoperative LAM usage #3 M, preoperative viral
load §10
6 cps/ml, presence of LFpreSDel mutation, membra-
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HBsAg. After adjusting for other confounding factors, only the
presence of LFpreSDel (HR, 3.766 [1.735–8.176], P=0.001) and
viral load §10
6 copies/mL (HR, 2.368 [1.127–4.977], P=0.023)
were independent predictors for hepatitis B relapse (Table 1).
Of the 150 patients included, LFpreSDel mutation data was
obtained in 136 patients. In these patients, hepatitis B relapse
occurred in 4 of 5 (80.0%) patients carrying both high HBV-
DNA levels (§10
6 copies/mL) and LFpreSDel mutations; in 17
of 55 (30.9%) patients carrying only one of the two conditions;
Figure 1. Clinical outcomes of the patients included and clinical factors related to OS or hepatitis B relapse free survival. (A) Clinical
outcomes of 150 patients receiving LT. Hepatitis B (HepB) relapse did not occur in 8 patients who developed YMDD mutants and were switched to
adefovir therapy before LT (left branch), whereas HepB relapse occurred in the remaining 142 patients who did not develop YMDD mutants. The
clinical consequences of these patients were illustrated. The 33 patients with hepatitis B relapse were marked by a shaded background. (B)
Comparison of OS between patients with (dashed line) and without (solid line) hepatitis B relapses. (C) Comparison of hepatitis B relapse free survival
between patients receiving longer (.3 months; solid line) and shorter (#3 months; dashed line) durations of pre-LT LAM treatment.
doi:10.1371/journal.pone.0032189.g001
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Meier analysis identified three subgroups with significantly
different hepatitis B relapse free survival (Figure 3E). Four of 5
patients with two risk factors experienced hepatitis B relapse
within two years after LT. In patients with only one risk, the
cumulative relapse rates were 15.6% in the first year, 29.7% in
the third year, and 44.4% in the fifth year, respectively. However,
in patients without any risk, the cumulative relapse rates in the
first, third, and fifth year were 6.7%, 8.4%, and 17.6%,
respectively. Finally, of the 136 patients analyzed, 17 (12.5%)
patients experienced reappearance of both HBsAg and HBV-
DNA. Of these patients, 2 of 5 (40.0%), 10 of 55 (18.2%), and 5
Figure 2. Association between hepatitis B relapse free survival and the genotypic features of HBV. (A) Detection of the LFpreSDel
mutants. After PCR amplification of the HBV pre-S sequence, the product was submitted for Southern blot analysis using a specific probe. N, 15 pg of
pCR2.1-TOPO vector DNA as a negative hybridization control; P, 15 pg of positive PCR product as a positive control; WT, wild type pre-S sequence. (B)
Comparison of hepatitis B relapse free survival between patients with high (.10
6 copies/mL; dashed line) and low (#10
6 copies/mL; solid line) viral
loads. (C) Comparison of hepatitis B relapse free survival between patients with (dashed line) and without (solid line) LFpreSDel mutation. (D)
Comparison of hepatitis B relapse free survival between patients with (dashed line) and without (solid line) basal core promoter A1762T/G1764A
mutation. (E) Comparison of hepatitis B relapse free survival between patients with (dashed line) and without (solid line) precore G1896A mutation.
doi:10.1371/journal.pone.0032189.g002
Predictors for HBV Relapse Post LT
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32189Figure 3. Immunohistochemical analysis of the explanted livers and risk score analysis. (A) Immunohistochemical analysis of HBsAg. Solid
arrow, cytoplasmic staining pattern; Empty arrow, membranous staining pattern. (B) Immunohistochemical analysis of HBcAg. Solid arrow, nuclear
HBcAg; Empty arrow, cytoplasm HBcAg. (C) Comparison of hepatitis B relapse free survival between patients with different staining patterns of
HBsAg. Solid line, cytoplasmic pattern; Dashed line, membranous patter. (D) Comparison of hepatitis B relapse free survival between patients with
different staining intensities of HBsAg. Solid line, intensity score #2; Dashed line, intensity score .2. (E) Combination of two independent risk factors
(viral load and LFpreSDel) to predict hepatitis B relapse free survival after LT. Blue line, risk score=0; Green line, risk score=1; Red line, risk score=2.
doi:10.1371/journal.pone.0032189.g003
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mentioned subgroups.
Discussion
Prophylactic administration of HBIG and preoperative usage of
nucleos(t)ide analogs followed by life-long therapy are regarded as
standard treatments for LT in HBV related end stage liver
diseases. However, with an increasing number of approved oral
antiviral agents, such as entecavir or tenofovir [26], it is now
arguable whether LAM remains the first choice of virus-
suppressing drugs for these patients. Furthermore, the dosage
and duration for HBIG administration become disputable since
potent life-long antiviral agents are now available. High dose or
long-term HBIG costs expensively and a schedule of frequent
injections is very inconvenient for patients. More and more recent
investigation have reported the withdraw of long-term HBIG in
patients receiving maintenance nucleos(t)ide analogue and out-
come seems good especially in low risk patients [27,28]. Due to
financial consideration and limitation of health insurance policy,
we adopted a short-term HBIG prophylaxis protocol in combi-
nation with life-long LAM therapy in our transplantation center.
The prophylaxis protocol using short-term HBIG and life-long
LAM therapy has also been reported by Nath et al [29]. In a mean
follow-up period of 2 years, one of 14 patients remained HBsAg-
positive but had normal liver function. In our cohort with more
enrolled patients and longer follow-up period, however, the overall
HBV relapse rate was quite high in comparison with other series
applying high dose or long term HBIG. To address this issue, we
performed this retrospective study to understand the limitation of
adapting this preventive strategy.
As shown in the literature, positive HBV-DNA or high
preoperative viral load before LT has always been identified as
an important predictor for hepatitis B relapse after LT [18,19]. In
consistent with previous studies, the present data indicated that
preoperative viral load greater than 10
6 cps/mL was an
independent risk factor for hepatitis B relapse after LT. In this
study, however, an even stronger predictor was identified, which is
the presence of LFpreSDel mutation. The pre-S region of HBV
large surface protein mediates many essential functions in HBV
life cycle, including virion morphogenesis and maturation,
formation of secretory filamentous surface particles, and presen-
tation of the putative receptor attachment site. Lines of evidence
also indicated that this region contained important immunogenic
epitopes, associated with effective host immune responses. Pre-S
deletion was found in several HBV related chronic liver diseases
and hepatocellular carcinoma [30,31]. This kind of mutations has
long been suspected to associate with hepatocarcinogenesis.
Our recent study showed that pre-S deletions could be further
divided into two types, one with short fragment (,100 bp) deletion
and the other with large fragment deletion (.100 bp) [24].
Sequencing data from previous studies showed that short fragment
pre-S deletions were usually in-frame and located in a region
surrounding the pre-S2 initiation codon, leaving the carboxyl 2/3
portion of the pre-S2 region largely intact. On the other hand, the
positions of LFpreSDels were poorly defined and randomly
distributed in the whole pre-S region. Conceivable, the immuno-
genic epitopes in the pre-S2 region had a better chance to be
preserved in the short fragment pre-S deletion mutants compared
with the LFpreSDel mutants. Previously, the short but not the
large pre-S deletion was found to associate with postoperative
recurrence of HCC. In the present study, we found that the large
but not the short fragment pre-S deletion was associated with
hepatitis B relapse post LT. Interestingly, a strong association was
found between the present of LFpre-SDel and a lower Ishak
histological score in the explanted livers, suggesting an immune
escape like mechanism. In light of previous findings that important
immunogenic epitopes were located in the pre-S2 region, which
could be interrupted by LFpreSDel, we speculated that recipients
infected with LFpreSDel mutants were less likely to be protected
by HBIG prophylaxis. Therefore, a higher risk of hepatitis B
relapse was found in such patients. Similarly findings have been
reported by Grottola et al when evaluating the pre-S/S region of
14 HBV-positive candidates for LT, in whom hepatitis B relapse
occurs after LT in 9 of them [32]. They found that the number of
nucleotide mutations in the pre-S2 region was significantly higher
in patients with hepatitis B relapse, compared with that in patients
without HBV relapse. It is possible that extensive modification of
pre-S2 protein (or develop of LFpreSDel in our cases) leads to
conformational change, interfering with the viral envelopment and
secretion processes. As a result, the mutant viruses re-infecting the
donor liver tend to accumulate inside the hepatocytes, contribut-
ing to the failure of HBIG prophylaxis.
In the univariate analysis, there were two histopathologic factors
(membranous HBsAg staining pattern and high HBsAg staining
intensity) significantly associated with HBV relapse free survival.
Unfortunately, neither of them constituted an independent
predictor in multivariate analysis. Despite that, in medical facilities
Table 1. Multivariate Cox proportional hazard regression analysis of the clinicopathologial and virological parameters for hepatitis
B relapse free survival after LT.
Parameter Comparison Hazard ratio (95% CI) P value
Duration of preoperative LAM treatment .3M 1
#3 M 2.989 (0.702–12.723) 0.138
Predominant HBsAg staining pattern Cytoplasmic 1
Membranous 3.249 (0.409–25.799) 0.265
HBsAg staining intensity (score 1 to 4) 0–2 1
3–4 2.070 (0.664–13.882) 0.152
Preoperative viral load ,10
6 cps/mL 1
§10
6 cps/mL 2.368 (1.127–4.977) 0.023
LFpreSDel (.100 bp) Absence 1
Presence 3.766 (1.735–8.176) 0.001
doi:10.1371/journal.pone.0032189.t001
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histopathologic factors can be used as surrogate predictors. In fact,
membranous HBsAg staining pattern and high HBsAg staining
intensity could imply a high level of serum HBV-DNA.
Genotypic features of HBV, such as viral genotypes and
mutations, were strongly associated with HBV pathogenesis as well
as the pre- and post- LT clinical outcomes [33,34,35]. To our
knowledge, the present study was the largest series extensively
evaluated the impact of HBV virological characteristics on viral
relapse after LT. In contrast to pre-S deletions, the other
virological factor, such as precore/core variants, was not found
to be associated with hepatitis B relapse in this study. Similar
findings were reported by Lo et al and Gaglio et al, indicating that
precore/core mutations did not influence hepatitis B relapse or
outcome [35,36]. On the other hand, the viral genotype has been
reported to have impact on patient’s outcome in LT [35]. In view
of HBV relapse after LT, Lo et al reported that the cumulative
rate of viral breakthrough due to LAM-resistance at 3 years was
4% for genotype B and 21% for genotype C (P=0.017). However,
Gaglio et al reported one of 8 (12.5%) patients with genotype B
had HBV relapse compared to one of 18 (5.5%) patients with
genotype C. Our data also supported that genotype did not
influence the outcome of HBV relapse after LT.
The major concern in the presented study is the relatively high
rate of HBV relapse after LT. In this study, hepatitis B relapse was
defined as reappearance of HBsAg. As such, 33 over 150 patients
(22%) met the criteria during a median follow-up period of more
than 3 years. However, if a more stringent definition was adopted,
such as reappearance of both HBsAg and HBV-DNA, only 12%
of our patients (18 patients) were considered hepatitis B relapse.
The high incidence of HBV relapse might be related to our anti-
viral prophylaxis. In the present study, only short-term HBIG was
used during the first week after LT. The viral DNA was not
detected initially because viral replication was effectively inhibited
by LAM. Fifteen of 33 patients with HBsAg relapse remained
HBV-DNA negative at the end of follow-up with normal liver
function. Unfortunately, prolonged usage of LAM resulted in drug
resistance in 15 of 18 HBV-DNA relapse patients. According to
the presented study, two independent risks were identified (high
viral load and LFpreSDel mutation) for HBV relapse after LT. As
such, only 6.6% of our patients in the low risk group experienced
hepatitis B relapse, suggesting the current strategy might be
adequate for the low risk patients. However, more aggressive
prophylactic protocol should be applied for those patients with one
or more risks, such as long-term HBIG [37] or replacement of
LAM by Entecavir [26]. Additionally, with the availability of a
more potent and state-of the-art antiviral regimen, such as
tenofovir or entecavir, the need for continuous HBIG-prophylaxis
is heavily challenged.
In conclusion, by analyzing preoperative clinical, virological
and histopathological factors, we discovered that high viral load
and LFpreSDel mutation were two independent predictors for
hepatitis B relapse after LT. In patients presented with neither risk
factor, it might be adequate to use short-term HBIG and life-long
LAM prophylaxis, whereas more aggressive prophylactic strategy
should be considered if patients were presented with one or both
risk factors.
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